Evaluation of the effect of microneedling and N-acetylcysteine in the treatment of vitiligo

Comparison of Effectiveness, Morbidity, Tolerability and Satisfaction of Vitiligo Treatment with Microneedling with N-acetylcysteine Mesotherapy Compared with Microneedling alone: a Randomized Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200826048531N1

Enrollment

Registered

2022-02-10

Start date

2021-12-22

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: We use 1-2 cc of Exir Pharmaceutical Company N-acetylcysteine 5% ampoule on the lesion and microneedle with NESOYA microneedling device until occurring the pinpoint

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: People with vitiligo have symmetrical constants patches They are between 15-75 years old No progressive or new lesions for at least the past year They have not been treated in the last two months

Exclusion criteria

Exclusion criteria: Patients who have thyroid disorders Patients with hypertrophic and keloid scars. At the site of microneedling have pathological lesions, wounds and infections. Patients who have allergies to N-acetylcysteine . Patients who are pregnant or breastfeeding. Patients who plan to become pregnant within the next six months.

Design outcomes

Primary

Measure	Time frame
Tensity of lesions. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: use of Vitiligo Extent Tensity Index (VETI) score.;Intensity of repigmentation. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: use of Vitiligo Extent Tensity Index (VETI) score.	—

Measure

Time frame

Tensity of lesions. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: use of Vitiligo Extent Tensity Index (VETI) score.;Intensity of repigmentation. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: use of Vitiligo Extent Tensity Index (VETI) score.

—

Secondary

Measure	Time frame
Treatment Tolerance. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: questionnaire (Scoring to pain from 0 to 10).;Therapeutic satisfaction. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: questionnaire (Scoring from 0 to 10).	—

Measure

Time frame

Treatment Tolerance. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: questionnaire (Scoring to pain from 0 to 10).;Therapeutic satisfaction. Timepoint: At the beginning of the study (before the intervention) and 2, 4, 6, 8, 10 and 14 weeks after starting treatment. Method of measurement: questionnaire (Scoring from 0 to 10).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Ziaeifar

Iran University of Medical Sciences

elhamziaeifar@gmail.com+98 21 6435 2390

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026